• Molecular NameFramycetin
  • SynonymFramycetinum [INN-Latin]; Neomycin B; Streptothricin B
  • Weight614.65
  • Drugbank_IDDB00452
  • ACS_NO119-04-0, 1404-04-2, 25389-98-4
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-10.95
  • pkaN/A
  • LogD (pH=7, predicted)-16.31
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.21
  • LogSw (predicted, AB/LogsW2.0)752.14
  • Sw (mg/ml) (predicted, ACD/Labs)1000.0
  • No.of HBond Donors19
  • No.of HBond Acceptors19
  • No.of Rotatable Bonds9
  • TPSA353.11
  • StatusFDA approved
  • Administrationoral, topical
  • PharmacologyAn antibiotic of the aminoglycoside class similar to neomycin.
  • Absorption_valueN/A
  • Absorption (description)Neomycin sulfate is poorly absorbed from the normal gastrointestinal tract.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding15.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionThe unabsorbed portion of the drug (approximately 97%) is eliminated unchanged in the feces.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most common adverse reactions to oral neomycin sulfate are nausea, vomiting, diarrhea, and malabsorption syndrome characterized by increased fecal fat, decreased serum carotene and fall in xylose absorption has been reported with prolonged therapy. Nephrotoxicity, ototoxicity and neuromuscular blockage have been reported.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A